REBLOZYL (luspatercept-aamt) for injection

REBLOZYL is a prescription medicine used to treat anemia (low red blood cells) in adults with beta thalassemia who need regular red blood cell (RBC) transfusions. REBLOZYL is not for use as a substitute for RBC transfusions in people who need immediate treatment for anemia.

Home | (luspatercept-aamt) for injection

REBLOZYL (luspatercept-aamt) for injection Price In India and Overseas
REBLOZYL (luspatercept-aamt) for injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

REBLOZYL (luspatercept-aamt) for injection

Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

REBLOZYL is a prescription medicine used to treat anemia (low red blood cells) in adults with:
 beta thalassemia who need regular red blood cell (RBC) transfusions.
 myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with
ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need regular RBC transfusion and have not
responded well to or cannot receive an erythropoiesis stimulating agent (ESA).

Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.
Luspatercept is indicated for the treatment of adults with transfusion-dependent anaemia associated with beta thalassaemia.

Drug (Brand / Generic): REBLOZYL / luspatercept-aamt
Current Indications: anemia (low red blood cells)
Marketed by:: Celgene Corporation
Approval Date: 2019

Available as (Form & Strength):
For injection: 25 mg lyophilized powder in a single-dose vial for reconstitution
For injection: 75 mg lyophilized powder in a single-dose vial for reconstitution

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.